emerg
drug
resist
among
caus
organ
respiratori
tract
infect
repres
critic
challeng
global
health
care
commun
although
vaccin
prevent
diseas
vaccin
develop
imped
sever
factor
therefor
novel
approach
treat
manag
respiratori
infect
urgent
need
passiv
immun
repres
possibl
altern
meet
need
immunoglobulin
antibodi
igi
yolk
chicken
egg
previous
use
bacteri
viral
infect
human
anim
advantag
includ
lack
reaction
mammalian
fc
receptor
low
product
cost
eas
extract
compar
mammalian
igg
higher
target
specif
greater
bind
avid
also
possess
remark
pathogenneutr
activ
respiratori
tract
lung
review
provid
overview
avian
igi
describ
potenti
therapeut
applic
prevent
treatment
respiratori
infect
articl
histori
respiratori
tract
infect
rti
repres
one
common
ill
encount
clinic
medicin
develop
countri
rti
account
major
antibiot
prescript
lost
workday
medic
consult
million
children
year
die
acut
respiratori
infect
ari
worldwid
everi
year
repres
caus
death
one
third
children
five
year
develop
countri
multidrugresist
mdr
difficulttotreat
pathogen
enorm
challeng
global
health
care
commun
high
morbid
mortal
associ
well
econom
burden
place
patient
health
care
system
antibiot
major
tool
manag
infect
caus
pathogen
emerg
antibiot
resist
undermin
use
case
furthermor
substanti
proport
respiratori
infect
acut
viral
infect
manag
infect
includ
use
antivir
treatment
reliev
diseas
symptom
howev
antivir
agent
target
conserv
viral
protein
place
select
pressur
viru
lead
develop
antivir
resist
viral
infect
prevent
vaccin
vaccin
develop
face
multipl
challeng
includ
antigen
variat
viral
strain
low
efficaci
shortterm
immun
respons
case
outbreak
rapid
vaccin
develop
may
possibl
control
spread
infect
therefor
urgent
need
exist
develop
novel
approach
treat
manag
respiratori
infect
passiv
immun
offer
altern
approach
treat
infect
immunecompromis
individu
avoid
side
effect
might
result
vaccin
antibodi
prepar
use
passiv
immun
mainli
contain
polyclon
antibodi
deriv
sera
immun
anim
immun
human
case
convalesc
patient
effect
use
polyclon
antibodi
face
sever
challeng
includ
standard
patient
safeti
monoclon
antibodi
mab
suggest
altern
polyclon
antibodi
use
limit
high
product
cost
us
addit
possibl
viral
escap
mutant
requir
product
numer
mab
target
sever
antigen
strategi
would
increas
cost
requir
addit
efficaci
safeti
studi
immunoglobulin
ig
ys
produc
chicken
bird
reptil
amphibian
function
igi
similar
mammalian
igg
igi
present
sera
chicken
pass
embryo
egg
yolk
egg
igi
antibodi
previous
use
bacteri
viral
infect
igi
well
toler
chicken
egg
natur
part
human
diet
addit
use
patient
egg
allergi
purifi
igi
contain
egg
albumin
common
trigger
allerg
reaction
egg
moreov
immunogen
igi
test
previous
pig
mice
vega
et
al
torch
et
al
demonstr
administr
igi
pig
via
system
local
rout
induc
antiigi
antibodi
respons
primarili
consist
igg
subclass
data
suggest
igi
antigen
although
biochem
properti
antibodi
molecul
facilit
consider
bind
mammalian
fc
receptor
serum
sick
theoret
possibl
igi
administ
larg
amount
whether
igi
elicit
allerg
respons
pig
unknown
howev
akita
et
al
demonstr
administr
egg
yolk
contain
igi
purifi
igi
igi
fab
mice
fail
induc
ige
respons
determin
littl
cross
reactiv
egg
white
protein
highli
allergen
purifi
igi
igi
react
human
complement
system
fc
receptor
risk
inflamm
minim
igi
thought
work
bind
bacteria
virus
lead
elimin
gut
prevent
bacteri
replic
viru
spread
case
passiv
immun
use
igi
antibodi
rapid
local
onset
action
given
patient
activ
infect
also
use
immatur
impair
immun
respons
infant
immunocompromis
adult
addit
advantag
igi
high
content
sialic
acid
report
increas
halflif
drug
compar
lower
sialic
acid
content
find
suggest
igybas
therapi
could
longer
circul
halflif
could
increas
efficaci
infect
aim
review
highlight
potenti
use
specif
igi
immunotherapi
prevent
treatment
respiratori
tract
infect
passiv
immun
administr
preform
antibodi
immunoglobulin
treat
variou
infecti
diseas
passiv
immun
either
natur
acquir
matern
antibodi
transfer
offspr
deliv
protect
pathogen
repres
natur
passiv
immun
bird
egg
yolk
reservoir
circul
igi
enter
embryon
circul
develop
embryo
matern
igi
provid
protect
short
time
week
level
chick
blood
decreas
rapidli
week
hatch
young
bird
begin
synthes
antibodi
passiv
immun
also
artifici
induc
transfer
antibodi
serum
deriv
immun
subject
nonimmun
subject
system
intraven
oral
rout
owe
shortterm
natur
passiv
immun
continu
suppli
preform
antibodi
need
requir
produc
larg
scale
product
larg
quantiti
igi
antibodi
egg
yolk
achiev
via
hyperimmun
chicken
process
includ
immun
hen
specif
antigen
regular
interv
continu
product
igi
egg
yolk
extract
igi
egg
yolk
ensur
constant
suppli
antibodi
passiv
immun
first
introduc
year
ago
albert
calmett
other
passiv
immun
principl
sinc
extens
use
treat
prevent
diseas
human
expect
advantag
antibodybas
treatment
absenc
offtarget
resist
alter
distribut
host
flora
treatment
target
specif
diseasecaus
pathogen
intranas
antibodi
prophylaxi
base
passiv
immun
principl
report
show
promis
viral
respiratori
infect
anim
model
includ
respiratori
syncyti
viru
rsv
influenza
viru
sendai
viru
expect
show
good
efficaci
human
clinic
trial
influenza
b
virus
coxsacki
viru
rhinovirus
howev
studi
show
low
antivir
efficaci
antibodi
use
suggest
result
might
attribut
low
level
viralspecif
antibodi
immunoglobulin
ig
prepar
use
evid
matern
igi
transfer
chicken
egg
yolk
embryo
protect
first
report
year
ago
immun
hen
product
egg
yolk
igi
antibodi
could
permit
effici
product
larg
quantiti
antibodi
mg
total
igyegg
antibodi
could
turn
provid
use
biolog
altern
specif
antivir
therapi
sever
respiratori
infect
igi
highli
stabl
ph
aqueou
condit
retain
antigenbind
activ
presenc
pepsin
ph
characterist
make
good
candid
type
process
applic
largescal
rel
simpli
product
igi
togeth
eas
transport
storag
make
good
candid
global
therapeut
use
time
pandem
use
igi
antibodi
accept
practic
sinc
also
veterinari
offic
swiss
govern
offic
approv
practic
human
igi
shown
effect
prevent
treatment
acn
dermatolog
infect
also
use
candidiasi
dental
cari
periodont
oral
caviti
gastriti
helicobact
pylori
intestin
disord
celiac
diseas
cholera
diarrhea
metabol
syndrom
ill
caus
environment
factor
noroviru
dust
mite
snake
venom
group
previous
develop
reliabl
murin
model
h
pylori
infect
addit
develop
igi
antibodi
chicken
target
pathogen
h
pylori
strain
use
antibodi
treat
infect
mice
passiv
immun
mice
significantli
lower
degre
infect
gastriti
unimmun
anim
oral
administr
antih
pylori
igi
use
complementari
therapi
combin
routin
antibiot
therapi
igi
caus
agglutin
pathogen
viru
bacteri
fungal
lead
immobil
facilit
remov
gut
adherenceblockad
inhibit
adhes
shown
main
mechan
igi
action
pathogen
vitro
experi
vivo
demonstr
igi
prevent
escherichia
coli
adher
intestin
mucu
piglet
igi
also
found
bind
expos
factor
surfac
gramneg
bacteria
fimbria
pili
flagella
lipopolysaccharid
outer
membran
protein
bind
igi
block
impair
function
growthrel
compon
bacteria
also
possibl
specif
igi
bind
bacteria
could
alter
cellular
signal
process
lead
decreas
toxin
product
releas
sever
studi
suggest
igi
enhanc
phagocyt
activ
invad
pathogen
exampl
igi
improv
phagocytosi
staphylococcu
aureu
neutrophil
well
phagocyt
activ
e
coli
milk
macrophag
polymorphonuclear
neutrophil
leukocyt
studi
also
shown
bind
specif
igi
surfac
salmonella
typhimurium
e
coli
lead
structur
alter
detect
use
electron
cloud
andor
electr
field
bacteri
surfac
chang
increas
suscept
bacteri
cell
phagocytosi
recent
vitro
studi
show
igi
opson
p
aeruginosa
augment
pmnmediat
respiratori
burst
subsequ
bacteri
elimin
research
found
viabl
bacteria
reduc
antip
aeruginosa
igi
use
opson
bacteria
prior
phagocytosi
figur
ad
igi
bacteri
suspens
caus
bacteri
clump
immobil
within
minut
opson
shown
indirect
immunofluoresc
addit
igi
enlarg
target
geometri
bacteri
aggreg
augment
phagocyt
effici
neutral
igi
prevent
intern
aureu
mammari
epitheli
cell
lead
neutral
bacteri
toxin
hand
igi
inhibit
celltocel
spread
viru
particl
thu
suppress
viral
colon
figur
structur
comparison
mammalian
igg
avian
igi
igi
antibodi
numer
advantag
first
natur
produc
avoid
environment
contamin
synthet
drug
addit
induc
specif
resist
direct
multipl
antigen
target
igi
antibodi
specif
target
particular
pathogen
affect
microbi
popul
host
consequ
induc
unpleas
side
effect
typic
antibiot
final
igi
antibodi
deposit
meat
henc
avoid
potenti
violat
regul
countri
forbid
use
antibiot
poultri
livestock
igi
antibodi
use
passiv
immunotherapi
also
advantag
addit
local
rapid
activ
pathogen
given
wide
rang
individu
age
rang
infant
adult
includ
immunodefici
patient
pregnant
women
natur
compon
egg
igi
antibodi
tend
nontox
store
month
powder
form
low
moistur
without
need
refriger
cheaper
faster
produc
vaccin
use
igi
antibodi
also
gener
advantag
context
immunotherapi
egg
collect
painfre
anim
friendli
benefici
perspect
anim
welfar
igi
greater
bind
avid
target
antigen
mammalian
igg
igi
antibodi
also
produc
conserv
mammalian
protein
easili
success
igg
antibodi
produc
mammal
due
evolutionari
distanc
mammal
bird
also
need
lower
antigen
quantiti
induc
effici
immun
respons
igi
store
egg
least
year
larg
quantiti
igi
antibodi
produc
one
chicken
gyear
antibodi
target
specif
exce
annual
product
four
rabbit
furthermor
product
egg
human
consumpt
alreadi
carri
industri
scale
make
low
cost
product
igi
larg
quantiti
technic
feasibl
igi
structur
chicken
iga
igm
structur
function
analog
mammalian
iga
igm
igi
differ
mammalian
igg
despit
similar
function
igi
predomin
serum
antibodi
bird
reptil
amphibian
lungfish
serum
concentr
far
exceed
iga
igm
igi
concentr
egg
yolk
iga
igm
found
egg
white
although
function
similar
exist
igi
igg
structur
markedli
differ
shown
figur
among
differ
h
chain
igi
one
variabl
region
vh
four
constant
region
ch
region
mammalian
igg
three
ch
region
also
igi
lack
hing
region
domain
make
less
flexibl
igg
one
use
characterist
igi
stabil
process
step
physiolog
condit
administr
igi
found
stabl
storag
room
temperatur
month
without
lose
activ
furthermor
igi
antibodi
store
year
without
signific
loss
activ
even
retain
activ
storag
month
room
temperatur
month
igi
prefer
store
longterm
storag
storag
caus
loss
activ
stabil
igi
affect
freezedri
although
repeat
freezethaw
cycl
might
compromis
activ
one
report
show
thermal
stabil
igi
affect
lyophil
minut
longterm
storag
igi
better
achiev
spray
dri
avoid
lose
antibodi
potenc
acid
stabil
igi
antibodi
report
ph
activ
decreas
lower
ph
valu
loss
activ
lower
ph
valu
might
due
conform
chang
distort
antigenbind
site
igi
antibodi
stabl
alkalin
condit
ph
lose
activ
ph
valu
safeti
safeti
major
way
igi
superior
mammalian
igg
igi
safer
igg
bind
human
fc
receptor
fix
mammalian
complement
compon
henc
trigger
potenti
danger
immun
respons
kubickova
et
al
expos
immort
human
lung
epitheli
cell
igi
use
lipopolysaccharid
posit
control
phosphatebuff
salin
neg
control
treatment
also
includ
exposur
human
goat
igg
exposur
last
hour
treatment
research
found
level
proinflammatori
cytokin
tumor
necrosi
factor
tnf
interleukin
il
granulocytemacrophag
colonystimul
factor
gmcsf
low
cell
cultur
treat
igi
compar
high
level
gmcsf
cell
treat
lipopolysaccharid
indic
igi
caus
inflammatori
respons
lung
cell
thu
safe
use
prevent
airway
infect
addit
oral
igi
antibodi
appli
treat
rotaviru
infect
human
treat
pulmonari
pseudomona
aeruginosa
infect
neg
side
effect
igi
treatment
observ
year
use
safeti
intranas
igi
deliveri
document
treatment
influenza
viru
acut
chronic
pharyng
human
use
igi
treatment
respiratori
infect
influenza
worldwid
influenza
virus
caus
million
hospit
death
annual
vaccin
antivir
drug
current
approach
prevent
treatment
infect
long
time
need
prepar
new
influenza
vaccin
month
new
strain
leav
popul
vulner
infect
avail
antivir
drug
limit
efficaci
viru
develop
resist
variant
differ
activ
target
bind
site
consequ
drug
effect
taken
beyond
third
day
infect
rapid
develop
new
treatment
influenza
critic
need
would
intensifi
pandem
situat
passiv
immun
potenti
deliv
prophylact
well
therapeut
effect
chicken
igi
test
use
passiv
immunotherapeut
prophylact
agent
influenza
virus
yang
et
al
produc
larg
quantiti
egg
yolk
igi
mgml
egg
yolk
week
immun
inactiv
viru
hemagglutin
inhibit
western
blot
assay
show
specif
bind
igi
antibodi
produc
hemagglutinin
neuraminidas
plaqu
reduct
assay
show
reduct
infect
igi
antibodi
vivo
studi
mous
model
show
igi
provid
protect
viru
reduc
infecti
titer
viru
lung
chang
normal
structur
weight
mous
lung
tissu
besid
antivir
effect
igi
research
also
show
protect
effect
compar
neuraminidas
inhibitor
oseltamivir
result
indic
igi
provid
highli
effect
altern
approach
treatment
influenza
tabl
pathogenspecif
titer
igi
typic
start
increas
egg
second
week
immun
peak
fifth
week
wen
et
al
isol
egg
yolk
igi
influenza
b
viru
immun
hen
inactiv
viru
igi
yield
mg
per
yolk
puriti
specif
bind
igi
viral
protein
demonstr
western
blot
hemagglutin
inhibit
test
research
use
plaqu
reduct
assay
demonstr
efficaci
specif
igi
neutral
influenza
infect
mdck
cell
vivo
studi
show
intranas
treatment
mice
prior
influenza
b
viru
infect
virusspecif
igi
protect
effect
reduc
viral
replic
lung
work
wen
et
al
show
igi
specif
influenza
b
readili
provid
good
altern
influenza
b
prevent
treatment
influenzaspecif
igi
administ
human
either
intranas
oral
could
serv
quick
safe
strategi
fight
pandem
influenza
tabl
pathogenspecif
igi
remain
sera
egg
immun
hen
least
month
vitro
investig
igi
produc
hen
immun
inactiv
influenza
virus
show
igi
produc
inhibit
homolog
well
heterolog
influenza
viral
strain
vivo
studi
mous
model
show
intranas
administr
igi
hour
prior
infect
protect
lethal
challeng
interestingli
igi
found
also
protect
apuerto
rico
anoth
studi
found
intranas
administr
igi
mice
lethal
infect
result
complet
recov
infect
anoth
interest
find
studi
presenc
igi
antibodi
egg
bought
directli
market
anoth
studi
test
efficaci
avian
igi
neutral
antibodi
pandem
influenza
viru
antibodi
deriv
ostrich
egg
immun
swine
influenza
viru
vaccin
strain
quantiti
igi
produc
larg
found
strong
crossreact
pandem
influenza
swine
influenza
viru
shown
elisa
immunocytochemistri
ostrich
igi
antibodi
found
inhibit
hemaggreg
activ
erythrocyt
induc
pandem
influenza
viru
igi
gener
found
inhibit
cytopatholog
effect
mdck
cell
upon
cocultur
antibodi
confirm
viral
neutral
cell
larg
amount
igi
gener
one
femal
ostrich
make
approach
costeffect
way
produc
igi
antibodi
pandem
influenza
viru
tabl
pseudomona
aeruginosa
patient
cystic
fibrosi
cf
cf
multisystem
autosom
recess
disord
affect
approxim
peopl
worldwid
cf
caus
dysfunct
cystic
fibrosi
transmembran
conduct
regul
cftr
protein
cftr
dysfunct
result
thick
secret
airway
lead
difficult
mucociliari
clearanc
pseudomona
aeruginosa
common
cf
patient
result
declin
lung
function
higher
morbid
mortal
erad
p
aeruginosa
difficult
patient
usual
experi
chronic
infect
characterist
chang
bacteria
cours
infect
algin
product
lead
greater
difficulti
pathogen
erad
antibiot
therapi
current
best
manag
approach
case
earli
intervent
target
bacteri
colon
step
prevent
chronic
stage
develop
later
intervent
fail
erad
p
aeruginosa
cf
patient
increas
risk
exacerb
bind
igi
p
aeruginosa
earli
cours
infect
prevent
adhes
bacteria
oropharynx
prevent
bacteri
colon
iga
vitro
purifi
igi
prepar
obtain
hen
immun
brsv
neutral
brsv
vitro
respiratori
mucosa
appear
role
initi
host
respons
help
reduc
bacteri
colon
consequ
cf
patient
iga
defici
could
greater
suscept
bacteri
colon
passiv
immun
igi
could
prophylact
augment
mucos
iga
immun
thu
increas
resist
p
aeruginosa
colon
igi
found
induc
rapid
compet
bacteri
clearanc
murin
pneumonia
model
studi
found
pulmonari
bacteri
load
antip
aeruginosa
igytr
mice
lower
control
hour
infect
igi
found
induc
rapid
declin
bacteri
load
within
first
hour
infect
igytr
mice
better
clinic
state
compar
control
may
attribut
lack
dissemin
infect
sinc
antip
aeruginosa
igi
protect
bacteremia
product
inflammatori
cytokin
accompani
faster
bacteri
clearanc
treat
mice
potent
mediat
inflamm
significantli
reduc
antip
aeruginosa
igytr
mice
compar
control
hour
infect
accordingli
pmn
mobil
granulocytecoloni
stimul
factor
gcsf
pmn
chemoattract
murin
analog
macrophag
inflammatori
significantli
decreas
hour
post
infect
antip
aeruginosa
igytr
group
compar
control
suggest
moder
neutropoiesi
consist
reduc
number
bacteria
lung
patholog
caus
p
aeruginosa
reduc
antibacteri
activ
igi
immunotherapi
tabl
prophylact
effect
intranas
administr
igi
antibodi
notabl
intranas
spray
hour
post
infect
superior
prophylact
treatment
could
due
presenc
igi
antibodi
airway
prepar
mucos
surfac
opsonophagocyt
process
reduc
interact
igi
opson
pathogen
antipseudomona
igi
shown
bind
p
aeruginosa
protein
flagellin
main
compon
flagellum
requir
motil
chemotaxi
bacteria
well
invas
establish
infect
host
activ
antipseudomona
igi
studi
use
electrophoresi
p
aeruginosa
strain
immunoblot
malditofm
result
reveal
igi
antibacteri
immunoreact
studi
strain
increas
potenti
use
prophylact
therapi
research
found
bind
igi
flagellin
hinder
host
invas
reduc
adher
bacteria
host
cell
cf
patient
figur
conclud
igi
might
directli
hinder
adher
indirectli
reduc
motil
bind
igi
flagellin
might
reduc
inflammatori
respons
p
aeruginosa
cf
patient
tabl
phase
feasibl
studi
cf
patient
ask
gargl
antipseudomon
igi
antibodi
everi
night
brush
teeth
practic
prolong
time
first
next
colon
specif
antipseudomon
igi
prophylaxi
experi
show
cultur
posit
p
aeruginosa
none
patient
becam
chronic
colon
howev
control
group
cultur
posit
patient
becam
chronic
colon
anoth
studi
demonstr
oral
administr
igi
p
aeruginosa
prevent
pulmonari
p
aeruginosa
infect
patient
cf
none
igytr
patient
studi
becam
chronic
colon
p
aeruginosa
compar
control
group
undesir
side
effect
report
igi
treatment
studi
period
tabl
nilsson
et
al
put
swedish
cf
patient
oral
prophylact
therapi
igi
antibodi
p
aeruginosa
year
cours
studi
continu
administr
azithromycin
use
sever
patient
cultur
test
posit
p
aeruginosa
includ
cultur
chronic
colon
antibiotictr
group
p
igi
group
n
two
sibl
chronic
colon
p
aeruginosa
compar
seven
patient
control
group
n
decreas
pulmonari
function
bodi
mass
index
igytr
patient
result
suggest
combin
use
igi
antibiot
treatment
prophylaxi
p
aeruginosa
potenti
prevent
p
aeruginosa
colon
delay
avoid
chronic
p
aeruginosa
infect
tabl
studi
antipseudomona
igi
possibl
complement
antibiot
insuffici
treatment
p
aeruginosa
infect
cf
lung
pmn
phagocytosi
fundament
determin
appropri
innat
immun
respons
bacteri
infect
dysfunct
pathway
caus
excess
bacteri
colon
lead
parenchym
infect
might
develop
sepsi
igi
observ
hydrophob
mammalian
igg
hydrophob
help
fc
portion
orient
opposit
antigen
expos
fcreceptor
interact
featur
increas
surfac
hydrophob
igi
suggest
increas
phagocyt
kill
p
aeruginosa
opson
figur
tabl
recent
clinic
studi
investig
use
polyclon
antipseudomona
igi
antibodi
prevent
p
aeruginosa
recurr
cf
patient
underway
clinicaltrialsgov
identifi
sever
acut
respiratori
syndrom
coronavirus
cov
known
caus
common
cold
vertebr
sever
acut
respiratori
syndrom
sar
cov
emerg
china
diseas
rapidli
spread
worldwid
caus
approxim
infect
mortal
rate
sar
outbreak
china
passiv
immun
use
sera
recov
sar
patient
show
posit
result
antisar
coronaviru
igi
evalu
isol
egg
yolk
pathogenfre
chicken
immun
sar
coronaviru
antigen
gener
igi
high
puriti
good
biolog
activ
igi
antibodi
abl
neutral
sar
coronaviru
dilut
result
neutral
experi
show
high
concord
elisa
result
effici
igi
alter
lyophil
potenti
make
transport
handl
easi
passiv
immun
shortterm
protect
evalu
use
experiment
infect
anim
model
antisar
igi
produc
studi
might
good
candid
mass
product
sarscov
immunotherapeut
tabl
case
outbreak
need
rapid
intervent
product
vaccin
take
longer
time
product
igi
antibodi
week
hen
vaccin
igi
product
use
igi
ab
outbreak
instead
vaccin
quit
unlik
time
fu
et
al
report
combin
vaccin
passiv
immun
drug
therapi
requir
effect
control
sar
tuberculosi
major
global
concern
human
anim
popul
diseas
caus
group
highli
relat
intracellular
pathogen
mycobacterium
tuberculosi
complex
mtbc
caus
human
morbid
mortal
worldwid
although
third
world
popul
latent
infect
mtb
develop
activ
tuberculosi
tb
tb
lead
caus
death
million
human
death
combin
tb
hivaid
develop
multidrugresist
strain
increas
diseas
burden
immunotherapi
might
present
new
option
treat
drugresist
tb
strain
promis
outcom
better
qualiti
life
intramuscular
immun
lohmann
lay
hen
show
increas
antimtbc
igi
antibodi
egg
yolk
peak
concentr
week
immun
specif
antibodi
persist
day
last
immun
studi
suggest
specif
antimtbc
igi
could
effect
approach
immunotherapi
tb
tabl
brsv
envelop
negativestrand
nonseg
rna
viru
main
caus
respiratori
diseas
young
calv
brsv
close
relat
human
rsv
hrsv
common
caus
lower
respiratori
tract
infect
children
worldwid
hrsv
result
million
hospit
annual
mortal
rate
children
year
licens
vaccin
effect
treatment
similar
two
virus
make
brsv
infect
calv
good
anim
model
studi
hrsv
purifi
igi
prepar
obtain
hen
immun
brsv
neutral
brsv
vitro
first
group
hen
immun
six
dose
immunogen
contain
tcid
ml
brsv
day
second
group
immun
two
dose
contain
brsv
day
vaccin
prepar
freund
complet
adjuv
first
dose
freund
incomplet
adjuv
follow
dose
first
group
bird
began
respond
third
immun
antibodi
titer
increas
maximum
fifth
immun
second
group
antibodi
detect
first
immun
high
titer
detect
second
immun
notabl
two
dose
need
induc
specif
neutral
antibodi
second
group
reduc
suffer
stress
bird
caus
repeat
inocul
specif
igi
obtain
brsv
second
group
present
highest
serum
neutral
antibodi
level
evalu
dot
blot
assay
igi
antibodi
abl
specif
recogn
viru
dilut
moreov
vitro
neutral
test
highest
neutral
antiigi
antibodi
titer
detect
fifth
immun
first
group
second
immun
second
group
find
suggest
immun
respons
could
improv
increas
amount
antigen
use
inocul
studi
conclud
igi
technolog
attract
tool
could
potenti
use
prophylaxi
andor
treatment
respiratori
diseas
caus
brsv
infect
tabl
promis
igi
antibodi
underscor
need
continu
research
improv
differ
aspect
product
includ
chicken
immun
protocol
adjuv
use
igi
extract
techniqu
method
increas
antibodi
yield
develop
monoclon
igi
antibodi
combin
advantag
mab
avian
igi
chicken
mab
antibodi
deriv
singl
bcell
lineag
undergon
repetit
round
somat
hypermut
clonal
select
usual
igi
isotyp
recogn
singl
uniqu
epitop
thu
chicken
mab
tend
specif
higher
affin
compar
polyclon
antibodi
counterpart
genet
engin
singlechain
fragment
variabl
igi
igyscfv
success
gener
base
phage
display
technolog
differ
research
group
spillner
et
al
potenti
conflict
interest
report
author
author
grate
financi
support
king
abdulaziz
citi
scienc
technolog
kacst
riyadh
saudi
arabia
provid
grant
merscov
special
program
project
number
aymn
talat
abba
http
sherif
ali
elkafrawi
http
